Filing Analysis
Entera Bio Ltd. announced the appointment of Dr. Riccardo Paolo Camisasca as the company's new Chief Medical Officer, effective August 18, 2026.
📋 Key Facts
- Dr. Riccardo Paolo Camisasca appointed as Chief Medical Officer (CMO) effective August 18, 2026.
- Dr. Camisasca brings over 30 years of experience in clinical development, medical affairs, and R&D leadership.
- Previous experience includes Global Head of R&D at Sumitomo Pharma Switzerland and leadership roles at Bial, Syneos Health, Takeda, and Novartis.
Entera Bio Ltd. filed an 8-K to announce its financial results for the three months ended June 30, 2026, and provided business updates via a press release.
📋 Key Facts
- Report date: August 7, 2026
- Reporting period: Three months ended June 30, 2026
- The filing includes financial results and business updates furnished in Exhibit 99.1
- Information is 'furnished' rather than 'filed' under Section 18 of the Exchange Act
Entera Bio Ltd. has completed a $275 million private placement of ordinary shares and pre-funded warrants to institutional investors, including BVF Partners L.P. The financing is intended to fund Phase 3 clinical studies for EB613 and general working capital.
🚩 Red Flags
- Significant dilution: Issuance of over 134 million securities in a single transaction.
- Board Control Shift: BVF Partners L.P. has gained significant influence, including the right to appoint two directors and a seat on the Nominating and Governance Committee.
- Planned Director Resignations: Two current independent directors (Haya Taitel and Yonatan Malca) have communicated they will resign or not stand for reelection once new independent directors are appointed as part of an 'orderly succession plan'.
- Equity Incentive Plan changes: Purchasers must vote to increase the number of shares available in the 2018 Equity Incentive Plan and restore executive ownership percentages.
📋 Key Facts
- Total proceeds: Approximately $275.0 million.
- Pricing: $2.04 per Ordinary Share (market price).
- Securities issued: 122,961,215 Ordinary Shares and 11,842,695 Pre-Funded Warrants.
- Closing Date: July 28, 2026.
- BVF Partners L.P. (BVF) granted rights to designate two directors to the Board.
- The company will file a registration statement within 30 days of the closing date for resale purposes.
Entera Bio Ltd. reported the results of its 2026 Annual Meeting of Shareholders, which included the election of three directors and approval of several shareholder proposals.
🚩 Red Flags
- Significant increase in authorized share capital (from 140M to 350M) suggests potential future dilution through equity raises.
📋 Key Facts
- Shareholders approved an amendment to the 2018 Equity Incentive Plan to increase the number of ordinary shares issuable by 2,500,000 shares.
- Shareholders approved an Articles Amendment to increase authorized Ordinary Shares from 140,010,000 to 350,000,000.
- Sean Ellis, Steven D. Rubin, and Geno H. Germano were elected to the Board of Directors for three-year terms.
- Kesselman & Kesselman (PwC member firm) was approved as independent auditors for fiscal year 2026.
- Various shareholder proposals regarding director compensation and executive officer compensation were approved.
Entera Bio Ltd. reported its financial results for the first quarter ended March 31, 2026, and provided general business updates. The report is a standard quarterly earnings disclosure furnished under Items 2.02 and 7.01.
📋 Key Facts
- Financial results cover the three-month period ended March 31, 2026
- Report filed and press release issued on May 8, 2026
- Miranda Toledano is the current Chief Executive Officer
- The company is headquartered in Jerusalem, Israel and trades on the Nasdaq Capital Market
Entera Bio Ltd. entered into a $10 million private placement agreement with BVF Partners LP to fund its Phase 3 clinical trial for EB613. The offering involves the issuance of units consisting of ordinary shares (or pre-funded warrants) and warrants to purchase additional shares.
🚩 Red Flags
- Significant potential dilution: Each unit carries 1.5 warrants, meaning the warrant coverage is 150%.
- Concentrated ownership: The investor (BVF Partners) has beneficial ownership caps set at 19.99%, indicating a major stake in the company.
📋 Key Facts
- Agreement signed on April 1, 2026, with closing on April 2, 2026.
- The company issued 7,827,789 units at a price of $1.2775 per unit.
- Total gross proceeds from the private placement are approximately $10.0 million.
- Each unit includes one ordinary share (or pre-funded warrant) and a warrant to purchase 1.5 ordinary shares.
- The ordinary share warrants have an exercise price of $1.24 and a five-year term.
- If all warrants are exercised for cash, the company would receive an additional $14.5 million.
- Proceeds are designated for the Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis.
Entera Bio Ltd. announced its financial results for the fiscal year ended December 31, 2025, and provided business updates. The information was furnished via a press release on March 27, 2026.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The report was signed by CEO Miranda Toledano on March 27, 2026.
- The company is an Israeli-based entity with ordinary shares and warrants listed on the Nasdaq Capital Market.
Entera Bio Ltd. announced the submission of its Phase 3 clinical trial protocol to the FDA for EB613, targeting postmenopausal women with osteoporosis. This submission marks a significant regulatory milestone as the company prepares to initiate a registrational trial.
📋 Key Facts
- Submitted Phase 3 protocol for EB613 to the FDA on March 4, 2026.
- The trial targets postmenopausal women with osteoporosis.
- The disclosure was made via a press release furnished under Item 7.01 Regulation FD.
- EB613 is the company's lead oral PTH (1-34) candidate.
Entera Bio Ltd. announced a leadership transition effective February 4, 2026, involving the appointment of Geno J. Germano as Chairman of the Board and the resignation of Gerald Lieberman from his roles as Chairman and Director.
🚩 Red Flags
- Simultaneous departure of the outgoing Chairman and appointment of a new one can sometimes signal internal shifts, though no disagreement was cited.
📋 Key Facts
- Geno J. Germano appointed as Class III director and Chairman of the Board, effective February 4, 2026.
- Germano is a 35-year veteran with significant leadership experience at Pfizer and Elucida Oncology.
- Gerald Lieberman resigned as Chairman and Director, effective immediately on February 4, 2026.
- The company stated Lieberman's resignation was not due to any disagreement regarding operations, policies, or practices.
- Germano is considered an independent director under SEC and Nasdaq rules.
Entera Bio Ltd. has amended its collaboration agreement with OPKO Health, Inc. to expand the scope of their partnership to include a new long-acting PTH tablet program for hypoparathyroidism. Additionally, the company announced changes to its Board of Directors, including the resignation of Gerald Ostrov and the appointment of Steven D. Rubin.
🚩 Red Flags
- The new director (Steven D. Rubin) is an Executive Vice President at OPKO Health, a primary collaborator in the expanded agreement, which may raise questions regarding board independence despite the company's assessment.
- Multiple material changes (agreement expansion and director turnover) occurring simultaneously.
📋 Key Facts
- Amended and Restated Collaboration Agreement signed on February 3, 2026, with OPKO Health, Inc. and OPKO Biologics Ltd.
- Expanded scope includes preclinical and clinical development of a daily long-acting PTH tablet (LA-PTH) for hypoparathyroidism.
- Development costs for the LA-PTH program will be shared equally (50/50) between Entera Bio and OPKO.
- Gerald Ostrov resigned from the Board effective February 1, 2026; resignation was not due to any disagreement with the company.
- Steven D. Rubin appointed as a Class III director, Audit Committee Chairman, and Compensation Committee member, effective February 1, 2026.
- Mr. Rubin is an executive at OPKO Health, indicating close ties between the two collaborating entities.
Entera Bio Ltd. filed an 8-K to furnish its quarterly financial results and business updates for the three months ended September 30, 2025.
📋 Key Facts
- Report date: November 14, 2025
- Reporting period: Three months ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Information is 'furnished' rather than 'filed' under Section 18 of the Exchange Act.
Entera Bio Ltd. filed an 8-K to announce its financial results and business updates for the three months ended June 30, 2025.
📋 Key Facts
- Report date: August 8, 2025
- Reporting period: Three months ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and business updates.
- Information is furnished under Item 7.01 rather than filed for purposes of Section 18 liability.
Entera Bio Ltd. announced that the FDA has agreed to a single, 24-month Phase 3 study design for its EB613 drug candidate in postmenopausal women with osteoporosis, using Bone Mineral Density (BMD) as the primary endpoint. This follows previous regulatory successes where the FDA waived requirements for certain nonclinical and carcinogenicity studies.
📋 Key Facts
- FDA agreed to a single multinational, randomized, double-blind, placebo-controlled Phase 3 study for EB613.
- Primary endpoint: Change in total hip Bone Mineral Density (BMD).
- Key secondary endpoint: Incidence of new or worsening vertebral fractures.
- The FDA previously waived requirements for comprehensive nonclinical developmental and reproductive toxicity (DART) studies on June 12, 2025.
- The FDA previously waived dedicated oral carcinogenicity studies on May 14, 2025.
Entera Bio Ltd. reported the final voting results from its 2025 Annual Meeting of Shareholders held on July 16, 2025. The meeting included elections to the Board and ratification of various executive compensation terms and auditor appointments.
📋 Key Facts
- Haya Taitel was elected to the Board of Directors for a three-year term (until 2028).
- Shareholders approved revised compensation terms/one-time grants for CEO Miranda Toledano, Chief of R&D Dr. Gregory Burshtein, and CFO Dana Yaacov-Garbeli.
- The Company's amended and restated compensation policy for directors and officers was ratified.
- Kesselman & Kesselman (PwC member firm) was re-appointed as independent auditors for the fiscal year ending December 31, 2025.
Entera Bio Ltd. filed an 8-K to announce its financial results and business updates for the three months ended March 31, 2025.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Information is furnished under Item 7.01 and not filed for purposes of Section 18 liability.
Entera Bio Ltd. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal mechanism to furnish the annual press release via Item 2.02.
📋 Key Facts
- Company announced financial results for the year ended December 31, 2024, on March 28, 2025.
- The filing includes a press release as Exhibit 99.1.
- Information is 'furnished' rather than 'filed' under Section 18 of the Exchange Act.
Entera Bio Ltd. entered into a strategic collaboration and license agreement with OPKO Health, Inc. to develop an oral delivery system for a GLP-1/glucagon dual agonist using Entera's N-Tab™ technology. As part of the deal, Entera issued 3,685,226 shares to OPKO for $8.0 million at approximately $2.17 per share.
🚩 Red Flags
- Significant dilution via issuance of 3.68M shares at a discount to recent trading activity (implied by the VWAP pricing mechanism).
- The $8.0 million is restricted in escrow for specific program costs, meaning it cannot be used for general corporate purposes or working capital.
- High dependency on a single partner (OPKO) and a specific technology platform/program.
📋 Key Facts
- Collaboration focuses on oral delivery of a dual agonist GLP-1/glucagon peptide (OPK-88006) for obesity and metabolic disorders.
- Entera granted OPKO an exclusive, sublicensable, worldwide license to use Entera's IP for this specific program.
- Revenue split: Entera retains 40% and OPKO retains 60% of Program proceeds; development costs are shared at a 40%/60% ratio.
- Opt-out provision: After Phase 1, Entera can opt out of funding, which would reduce their revenue share to 15% while OPKO assumes all funding and commercialization responsibility.
- Equity Issuance: Sold 3,685,226 ordinary shares to OPKO for $8.0 million (approx. $2.17/share).
- Lockup & Standstill: OPKO is subject to a 12-month lockup on the purchased shares and a 24-month standstill provision.
- Escrow Requirement: The $8.0 million proceeds are to be held in escrow specifically to fund development cost obligations under the agreement.
Entera Bio Ltd. filed an 8-K to submit legal opinions and consents from Herzog Fox & Neeman regarding the company's corporate status or specific securities issuance.
📋 Key Facts
- Filing date: January 10, 2025
- The filing is solely for the purpose of providing Exhibit 5.1 (Legal Opinion) and Exhibit 23.1 (Consent).
- Legal counsel identified as Herzog Fox & Neeman.
- CEO Miranda Toledano signed the report.
This is an amendment to a previous 8-K filing regarding the results of a shareholder advisory vote. The Board has decided to hold non-binding 'Say-on-Frequency' votes on executive compensation annually, following shareholder preference.
📋 Key Facts
- The filing is an Amendment (Form 8-K/A) to an original report filed on August 2, 2024.
- Shareholders voted at the Annual Meeting held on July 31, 2024.
- The 'one year' frequency option received the highest number of votes for advisory compensation voting.
- The Board determined that non-binding shareholder votes on executive compensation will occur every year until further notice.
Entera Bio Ltd. filed an 8-K to announce its financial results for the three months ended September 30, 2024. The filing serves as a formal vehicle to furnish quarterly earnings information via a press release.
📋 Key Facts
- The company announced financial results for the quarter ending September 30, 2024.
- The announcement was made on November 8, 2024.
- Financial results were provided in Exhibit 99.1 as a press release.
Entera Bio Ltd. filed an 8-K to furnish its quarterly financial results for the three months ended June 30, 2024. The filing serves as a formal announcement of the company's recent operational and financial performance.
📋 Key Facts
- The filing announces financial results for the period ending June 30, 2024.
- Report date is August 9, 2024.
- Financial results were provided via a press release furnished as Exhibit 99.1.
Entera Bio Ltd. reported the final voting results from its 2024 Annual Meeting of Shareholders held on July 31, 2024. The meeting included the election of two directors and several shareholder proposals regarding compensation and equity incentive plans.
📋 Key Facts
- Annual Meeting held on July 31, 2024.
- Miranda Toledano and Yonatan Malca were elected to the Board of Directors for three-year terms.
- Shareholders approved a one-time grant of compensation for CEO Miranda Toledano.
- Shareholders approved an amendment to the 2018 Equity Incentive Plan, increasing shares by 1,788,515.
- PwC (Kesselman & Kesselman) was ratified as independent auditors for fiscal year ending Dec 31, 2024.
Entera Bio Ltd. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results were released via press release on May 10, 2024.
- The report covers the period ending March 31, 2024.
Entera Bio Ltd. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal mechanism to furnish the earnings press release via Exhibit 99.1.
📋 Key Facts
- The company announced financial results for the fiscal year ended December 31, 2023.
- The announcement was made on March 8, 2024.
- Financial results were released via a press release furnished as Exhibit 99.1.
Entera Bio Ltd. announced that it has regained compliance with Nasdaq's minimum bid price requirement as of March 4, 2024.
🚩 Red Flags
- The necessity of this filing implies a recent history of being below minimum bid price requirements (delisting risk context).
📋 Key Facts
- The company successfully addressed the Nasdaq minimum bid price deficiency.
- Compliance was achieved as of the filing date, March 4, 2024.
- A press release detailing the compliance status is furnished in Exhibit 99.1.
Entera Bio Ltd. has filed a Form S-3 registration statement to register the resale of securities previously issued in a private placement conducted on December 22, 2023. This filing fulfills the company's obligations under a prior registration rights agreement.
🚩 Red Flags
- Potential future dilution: The filing registers shares and warrants that can be converted into common stock, which may lead to increased supply of shares on the open market upon exercise/resale.
📋 Key Facts
- The filing relates to a private placement consummated on December 22, 2023.
- The securities being registered for resale include ordinary shares issued in the private placement and ordinary shares issuable upon exercise of warrants.
- Warrants are exercisable at an exercise price of $5.85 per Ordinary Share (each warrant covers half of a share).
- The registration is being performed via Form S-3 as required by a previously entered registration rights agreement.
Entera Bio Ltd. has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 for at least 10 consecutive business days before June 24, 2024, to avoid delisting.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Explicit mention of potentially implementing a reverse stock split to regain compliance
- History of non-compliance (initial 180-day period expired on December 26, 2023)
📋 Key Facts
- Received a 180-day extension from Nasdaq on December 27, 2023.
- The deadline to regain compliance with the Bid Price Requirement is June 24, 2024.
- Compliance requires a closing bid price of at least $1.00 for 10 consecutive business days.
- Failure to comply may result in delisting from the Nasdaq Capital Market.